Dr. Wang on Sequencing Oral Agents in MCL

In Partnership With:

Partner | Cancer Centers | <b>MD Anderson</b>

Michael Wang, MD, discusses the sequencing of oral therapies in mantle cell lymphoma.

Michael Wang, MD, professor, Departments of Lymphoma/Myeloma and Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the sequencing of oral therapies in mantle cell lymphoma.

Implementing effective oral agents early in the treatment regimen is vital in patients with MCL, Wang says. This rationale applies to all oral therapies, not just ibrutinib (Imbruvica), Wang adds. Introducing the most efficacious treatment with the fewest adverse effects should drive the decision on which therapy to use, Wang stresses.

Beginning these treatment regimens early for patients with MCL allows for higher efficacy benefits, a longer duration of response, and lower toxicity, Wang continues. Specifically regarding ibrutinib, a pooled analysis demonstrated this plan of treatment action was effective, Wang concludes.